Journal
CURRENT OPINION IN ONCOLOGY
Volume 20, Issue 2, Pages 162-175Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCO.0b013e3282f335a3
Keywords
EGFR inhibitor; nonsmall cell lung cancer
Categories
Ask authors/readers for more resources
Purpose of review Inhibition of the epidermal growth factor receptor (EGFR) is now an established part of the treatment of nonsmall cell lung cancer. This review summarizes the clinical trials that have been performed with monoclonal antibodies and small molecule tyrosine kinase inhibitors targeting EGFR in nonsmall cell lung cancer. Recent findings Erlotinib has established second and third-line efficacy following the BR,21 study. Recently the INTEREST trial showed gefitinib to have an equivalent outcome to docetaxel in the second line setting. Numerous other tyrosine kinase inhibitor drugs and monoclonal antibodies have demonstrated clinical activity in phase I and phase 11 trials. Novel tyrosine kinase inhibitors may have the ability to overcome resistance to first generation tyrosine kinase inhibitor therapy. Furthermore there are encouraging studies combining EGFR inhibitors and antiangiogenesis drugs such as bevacizumab. Summary EGFR inhibition, by a range of strategies, remains a central node in the treatment of nonsmall cell lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available